Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $803,000.

  • Aytu Biopharma's Depreciation & Amortization (CF) fell 39.81% to $803,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 22.04%. This contributed to the annual value of $5.4 million for FY2025, which is 20.04% down from last year.
  • Aytu Biopharma's Depreciation & Amortization (CF) amounted to $803,000 in Q3 2025, which was down 37.94% from $1.3 million recorded in Q2 2025.
  • Aytu Biopharma's Depreciation & Amortization (CF)'s 5-year high stood at $3.3 million during Q2 2021, with a 5-year trough of $803,000 in Q3 2025.
  • Over the past 3 years, Aytu Biopharma's median Depreciation & Amortization (CF) value was $1.5 million (recorded in 2024), while the average stood at $1.6 million.
  • As far as peak fluctuations go, Aytu Biopharma's Depreciation & Amortization (CF) surged by 71.85% in 2021, and later crashed by 40.18% in 2024.
  • Over the past 5 years, Aytu Biopharma's Depreciation & Amortization (CF) (Quarterly) stood at $2.7 million in 2021, then decreased by 17.53% to $2.2 million in 2022, then declined by 18.81% to $1.8 million in 2023, then fell by 20.04% to $1.4 million in 2024, then tumbled by 39.81% to $803,000 in 2025.
  • Its last three reported values are $803,000 in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.